Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 241 to 250 of 1338 total matches.

Nedocromil for Asthma

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 1993  (Issue 900)
as a metered-dose inhaler for maintenance treatment of mild to moderate asthma. ACTIVITY — A pyranoquinoline ...
Nedocromil sodium (Tilade - Fisons), an anti-inflammatory drug similar to cromolyn sodium (Intal - Fisons), although chemically unrelated, is now available in the USA as a metered-dose inhaler for maintenance treatment of mild to moderate asthma.
Med Lett Drugs Ther. 1993 Jul 9;35(900):62-3 |  Show IntroductionHide Introduction

Imiquimod for Genital Warts

   
The Medical Letter on Drugs and Therapeutics • Dec 19, 1997  (Issue 1016)
factor and a variety of interleukins. Whether this cytokine cascade is responsible for its activity ...
Imiquimod (i mi kwi' mod) 5% cream (Aldara - 3M Pharmaceuticals) has been approved by the FDA for treatment of external genital and perianal warts (condyloma acuminata). The drug requires a prescription but is applied by the patient. It is the second patient-applied treatment to become available for external genital warts; the first was podofilox (Condylox - Medical Letter, 33:117, 1991).
Med Lett Drugs Ther. 1997 Dec 19;39(1016):118-9 |  Show IntroductionHide Introduction

Vazalore - A New Aspirin Formulation

   
The Medical Letter on Drugs and Therapeutics • May 02, 2022  (Issue 1649)
Vazalore with claims of fast, predictable absorption and antiplatelet activity and improved ...
The FDA has approved an over-the-counter (OTC) liquid-filled capsule formulation of aspirin (Vazalore – PLx Pharma). The manufacturer has been heavily promoting Vazalore with claims of fast, predictable absorption and antiplatelet activity and improved gastrointestinal safety compared to existing OTC aspirin formulations.
Med Lett Drugs Ther. 2022 May 2;64(1649):70-1 |  Show IntroductionHide Introduction

Linaclotide (Linzess) for Functional Constipation

   
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023  (Issue 1683)
intake, increased physical activity, and toilet training. If first-line treatment is ineffective ...
The guanylate cyclase-C receptor agonist linaclotide (Linzess – Abbvie/Ironwood) was first approved by the FDA in 2012 for treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults. The drug has now been approved for treatment of functional constipation in patients 6-17 years old. Linaclotide is the only drug to be approved in the US for treatment of functional constipation.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):135-6   doi:10.58347/tml.2023.1683d |  Show IntroductionHide Introduction

Prevention and Treatment of Nerve Gas Poisoning

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 1990  (Issue 831)
primarily at nicotinic sites to normalize skeletal muscle activity. Pralidoxime itself has little activity ...
With the possibility that chemical weapons may be used against United States armed forces in the Persian Gulf, the military has taken steps to protect our troops against poison gas, particularly ''nerve agents';'; (MA Dunn and FR Sidell, JAMA, 262:649, 1989).
Med Lett Drugs Ther. 1990 Nov 16;32(831):103-5 |  Show IntroductionHide Introduction

Felbamate

   
The Medical Letter on Drugs and Therapeutics • Nov 26, 1993  (Issue 910)
of seizures associated with the Lennox-Gastaut syndrome, a severe epileptic encephalopathy. ACTIVITY ...
Felbamate (Felbatol - Wallace Laboratories), a phenyl dicarbamate structurally similar to meprobamate (Equanil, and others), was recently approved by the US Food and Drug Administration for use alone or with other drugs in adults with partial seizures with or without secondary generalization. It was also approved for use in addition to other drugs in children with the multiple types of seizures associated with the Lennox-Gastaut syndrome, a severe epileptic encephalopathy.
Med Lett Drugs Ther. 1993 Nov 26;35(910):107-8 |  Show IntroductionHide Introduction

Nefazodone for Depression

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 1995  (Issue 946)
Neuropharmacol, 16:S45, 1993). The clinical significance of this activity is unknown. The Medical Letter, Vol ...
Nefazodone (Serzone - Bristol-Myers Squibb) was recently approved by the US Food and Drug Administration for treatment of depression. A phenylpiperazine, nefazodone is chemically related to trazodone (Desyrel, and others).
Med Lett Drugs Ther. 1995 Apr 14;37(946):33-5 |  Show IntroductionHide Introduction

Two Neuraminidase Inhibitors for Treatment of Influenza

   
The Medical Letter on Drugs and Therapeutics • Oct 08, 1999  (Issue 1063)
− Medical Letter, 35:109, 1993). Their use has been limited by lack of activity against influenza B, rapid ...
Zanamivir, a neuraminidase inhibitor taken by inhalation, has been approved by the FDA for treatment of influenza. Oseltamivir phosphate, an oral neuraminidase inhibitor, will probably be approved soon.
Med Lett Drugs Ther. 1999 Oct 8;41(1063):91-3 |  Show IntroductionHide Introduction

Lopinavir/Ritonavir: A Protease-inhibitor Combination

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001  (Issue 1095)
is a potent inhibitor of CYP3A4 activity and raises lopinavir plasma levels. When used in combination ...
Lopinavir/ritonavir is the first fixed-dose combination of protease inhibitors approved by the FDA for the treatment of HIV infection. It is being marketed for use with other drugs in adults and children more than six months old. Lopinavir is a new drug available only in this combination. Ritonavir is often used with other protease inhibitors to raise their plasma concentrations.
Med Lett Drugs Ther. 2001 Jan 8;43(1095):1-2 |  Show IntroductionHide Introduction

Bamlanivimab and Etesevimab for Post-Exposure Prophylaxis of COVID-19

   
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021  (Issue 1635)
activity than bamlanivimab alone, the FDA presumed it to be effective based on the results of BLAZE-2 Part ...
In February 2021, the FDA issued an Emergency Use Authorization (EUA) for the investigational monoclonal antibodies bamlanivimab and etesevimab (Lilly) for use together to treat mild to moderate COVID-19 in persons ≥12 years old who weigh ≥40 kg and are at high risk of progression to severe disease or hospitalization. The FDA has now expanded this EUA to allow use of the antibodies together for post-exposure prophylaxis of COVID-19 in such persons if they are not fully vaccinated against COVID-19 or are unlikely to have an adequate immune response to full vaccination and have...
Med Lett Drugs Ther. 2021 Oct 18;63(1635):163-4 |  Show IntroductionHide Introduction